Catheter Precision's VIVO technology demonstrated 90% accuracy in identifying VT origin at the European Society of Cardiology Symposium.

Catheter Precision, Inc. presented promising interim results at the European Society of Cardiology Symposium, showcasing its VIVO technology for identifying the origin of ventricular tachycardia (VT) in patients with scar-related re-entrant VT. The ongoing study at Warwick Medical School demonstrated a 90% accuracy rate compared to invasive mapping, with a procedural success rate of 90% at seven months. VIVO has received FDA clearance and aims to enhance patient care in the U.S.

September 05, 2024
3 Articles